stockrowVerastem, Inc.
VSTM Healthcare Biotechnology
Verastem, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $30.9 million, up 209.1% from fiscal 2024.
- Revenue
- +113.6%
- EPS
- +45.2%
- Free cash flow
- +24.5%
- Total debt
- +52.9%
Quarter to September 2026, against a year earlier
Follow VSTM
Alert me
Verastem, Inc. (VSTM) EV/Sales
As of 6 November 2026, Verastem, Inc. (VSTM) trades at a EV/Sales of 8.0×. Over the past ten years it has ranged from −5.6× (October 2022) to 235× (November 2021); the current reading is higher than 68% of that period. That is below the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 10.2× | (8.67%) |
| FY2024 | 11.1× | 115.01% |
| FY2022 | 5.2× | (95.88%) |
| FY2021 | 126× | 5,335.03% |
| FY2020 | 2.3× | (68.55%) |
| FY2019 | 7.4× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 7.6× | 101.56% |
| Jun 2026 | 3.8× | (55.76%) |
| Mar 2026 | 8.5× | (16.30%) |
| Dec 2025 | 10.2× | (55.68%) |
| 19 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| RAPP Rapport Therapeutics, Inc. compare | n/m |
| VOR Vor Biopharma Inc. compare | n/m |
| DRTS Alpha Tau Medical Ltd. compare | n/m |
| SPTX Seaport Therapeutics, Inc compare | n/m |
| SGP SpyGlass Pharma, Inc. compare | n/m |
| AVLN Avalyn Pharma Inc. compare | n/m |
| MNKD MannKind Corporation compare | 3.8× |
| VSTM Verastem, Inc. | 8.0× |
| INBX Inhibrx Biosciences, Inc. compare | 439× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)